EGFR and non-small cell lung carcinoma: Intriguing early data in support of this concept come from the interim analysis of the SINDAS trial, which randomized 133 patients with EGFR mutant NSCLC and synchronous oligometastatic disease to first-generation tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib, or icotinib) and radiotherapy (25–40 Gy in 5 fractions depending on tumor size/location) to all metastases and the primary tumor/involved regional lymphatics versus TKI alone (97).